Aarti Drugs has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API manufacturing facility located at MIDC, Tarapur, Maharashtra.
In September 2024, USFDA had concluded inspection at said facility. On conclusion of the inspection, the company had received 7 inspectional observations in Form 483, where none of the observations are related to Data Integrity.
Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.
